First Generation Tools for the Modeling of Capicua (CIC) - Family Fusion Oncoprotein-Driven Cancers
Cuyler LuckiD, Kyle A. JacobsiD, Julia RiadiD, Christopher D. MacaraigiD, Rovingaile Kriska PonceiD, Ross A. OkimotoiD
Abstract
Clinical divergence between patients harboring CIC-rearrangements is frequently observed. For example, the prototypical CIC::DUX4 fusion associates with soft tissue tumors while CIC::NUTM1 fusions typically localize to the CNS (brain/spinal cord). The basis for these differences is poorly understood due to a lack of molecular tools. To address this need, we generated patient-informed, synthetic coding sequences for CIC::NUTM1, CIC::LEUTX, and ATXN1::DUX4 and validated them in structure-function studies. We found that CIC::NUTM1 drives a transcriptional program distinct from that of CIC::DUX4 due to a C-terminal NUTM1 functional domain, CIC::LEUTX weakly activates CIC target genes through LEUTX transactivation sequences, and ATXN1::DUX4 upregulates CIC target genes via the ATXN1 AXH domain. Our findings indicate that the CIC fusion binding partner may alter overall fusion oncoprotein activity. Thus, these first generation synthetic tools provide an unprecedented resource to study CIC-family fusions beyond CIC::DUX4 and allow for the dissection of this rare subgroup of cancers. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=195 SRC="FIGDIR/small/653825v1_ufig1.gif" ALT="Figure 1"> View larger version (27K): org.highwire.dtl.DTLVardef@1c1cf27org.highwire.dtl.DTLVardef@1073faforg.highwire.dtl.DTLVardef@e61455org.highwire.dtl.DTLVardef@140e952_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein
Cuyler Luck, Kyle A. Jacobs, Ross A. Okimoto·Cancer Research CommunicationsPeer-reviewed·Nov 12, 2024
- Expression of the CIC-DUX4 fusion oncoprotein mimics human CIC-rearranged sarcoma in genetically engineered mouse models
P. G. Hendrickson, K. M. Oristian, … D. G. Kirsch·bioRxiv·Sep 26, 2023
- The CIC-DUX4 fusion oncoprotein drives metastasis and tumor growth via distinct downstream regulatory programs and therapeutic targets in sarcoma
R. A. Okimoto, W. Wu, … T. G. Bivona·bioRxiv·Nov 21, 2018
- Mapping chromatin state and transcriptional response in CIC-DUX4 undifferentiated round cell sarcoma
N. Thomas, C. Luck, … R. Okimoto·bioRxiv·Oct 11, 2023
- WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma.
R. K. Ponce, N. J. Thomas, … R. A. Okimoto·bioRxiv·Jun 21, 2021
- Antagonism among DUX family members evolved from an ancestral toxic single homeodomain protein
Darko Bosnakovski, Erik A. Toso, … Michael Kyba·iSciencePeer-reviewed·Sep 2, 2023